文献速递主动脉疾病

预防性术后升压药对胸主动脉腔内修复术结局的影响

Impact of Prophylactic Postoperative Vasopressors on Outcomes of Patients Undergoing Thoracic Endovascular Aortic Repair.
PubMed 文献 · Ann Vasc Surg · 2026-02-04

基于VQI数据库2012至2023年11342例TEVAR患者的多机构真实世界研究,2420例(21.3%)接受预防性术后升压药。校正混杂因素后,PPV与30天死亡率、MACE、术后脊髓缺血风险显著升高相关,提示需重新评估其应用。

要点

  • 接受预防性术后升压药的患者30天死亡率和MACE发生率显著更高。
  • 校正混杂因素后,PPV仍与30天死亡率(OR 3.23)、MACE(OR 2.18)、脊髓缺血(OR 1.46)风险升高独立相关。
  • 应基于患者合并症和危险因素个体化决策,并需前瞻性研究确认。

核心结论

  • 预防性术后升压药与TEVAR患者30天死亡率、MACE、脊髓缺血及其他不良结局的显著更高风险相关。
  • 应重新评估预防性术后升压药的作用,并基于患者合并症和危险因素进行个体化决策。
  • 需要前瞻性研究来确认这些发现。

研究设计与样本

  • 多机构真实世界回顾性研究,数据来源于血管外科学会血管质量倡议(VQI)数据库。
  • 纳入2012年3月1日至2023年1月28日期间接受TEVAR的患者。
  • 共审查25549例患者,其中11342例符合研究标准并纳入分析。
  • 采用单变量和多变量分析评估预防性术后升压药与术后结局的关联。

主要发现

  • 2420例(21.3%)患者接受了预防性术后升压药。
  • 接受PPV的患者30天死亡率显著更高(9.3% vs. 2.1%,P < 0.001)。
  • 接受PPV的患者MACE发生率显著更高(18.2% vs. 7.4%,P < 0.001)。
  • 接受PPV的患者术后脊髓缺血发生率显著更高(2.6% vs. 1.3%,P < 0.001)。
  • 接受PPV的患者其他不良事件发生率也显著更高。

关键数值与推荐

  • 校正混杂因素后,PPV与30天死亡率风险升高相关(OR 3.23,95%CI 2.58-4.04,P < 0.001)。
  • 校正混杂因素后,PPV与MACE风险升高相关(OR 2.18,95%CI 1.89-2.51,P < 0.001)。
  • 校正混杂因素后,PPV与术后脊髓缺血风险升高相关(OR 1.46,95%CI 1.05-2.01,P = 0.022)。
  • MACE定义为术后新发心肌梗死、充血性心力衰竭、心律失常或卒中。

临床怎么用

  • 临床应重新评估TEVAR术后预防性使用升压药的策略。
  • 是否使用升压药应基于患者合并症和危险因素进行个体化决策。

局限性

  • 本研究为回顾性数据库分析,可能存在未校正的混杂因素。
  • 需要前瞻性研究来确认预防性术后升压药与不良结局的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prophylactic postoperative vasopressors (PPVs) are used to induce hemodynamic augmentation to prevent spinal cord ischemia (SCI) in patients undergoing thoracic endovascular aortic repair (TEVAR). However, the scientific evidence on its effectiveness and safety is limited. This study aims to investigate the safety and effectiveness of PPV in patients undergoing TEVAR in a multi-institutional real-world setting. METHODS: All TEVAR patients in the Society for Vascular Surgery Vascular Quality Initiative database between March 1, 2012, and January 28, 2023, were identified. Univariable and multivariable analyses were performed to assess the association between the use of PPV and the rates of postoperative 30-day mortality, major adverse cardiovascular events (MACE, defined as new onset of postoperative myocardial infarction, congestive heart failure, dysrhythmias, or stroke), SCI, and other adverse events for patients undergoing TEVAR. RESULTS: Out of 25,549 reviewed patients, 11,342 underwent TEVAR, matching the study criteria, and were analyzed. A total of 2,420 patients (21.3%) received PPV. Patients who received PPV had significantly higher rates of 30-day mortality (9.3% vs. 2.1%, P < 0.001), MACE (18.2% vs. 7.4%, P < 0.001), postoperative SCI (2.6% vs. 1.3%, P < 0.001), and other adverse events. After adjusting for confounders, the use of PPV was associated with significantly increased odds of 30-day mortality (odds ratio [OR], 3.23, 95% confidence interval [CI]: 2.58-4.04, P < 0.001), MACE (OR, 2.18, 95% CI: 1.89-2.51, P < 0.001), postoperative SCI (OR, 1.46, 95% CI: 1.05-2.01, P = 0.022), and other adverse events. CONCLUSION: PPV was associated with significantly higher odds of 30-day mortality, MACE, SCI, and other adverse outcomes. The role of PPV should be re-evaluated, and the decision for administration should be made on an individualized basis, considering patient comorbidities and risk factors. A prospective study is required to confirm these findings.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Veranyan N, Yei K, Ilyas S, et al. Impact of Prophylactic Postoperative Vasopressors on Outcomes of Patients Undergoing Thoracic Endovascular Aortic Repair. Ann Vasc Surg. 2026. PMID: 41643851. doi:10.1016/j.avsg.2026.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。